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Commentary
The very public debate about potential 
  harmful consequences of exposure to the 
plastic monomer bisphenol A (BPA) is a lead-
ing high-profile battleground in a scientific 
revolu  tion currently under way in toxicology 
(Layton 2008; Myers et al. 2009). But much 
more is under contention than the health risks 
of one chemical. Data emerging from studies 
of endocrine-disrupting chemi  cals (EDCs), 
such as BPA, that mimic or in numerous 
ways interfere with hormone action, chal-
lenge the central assumption that has guided   
toxicology for centuries, including today’s 
regulatory apparatus for assessing chemical 
safety. In so doing, they challenge the meth-
ods and the adequacy of chemical exposure 
safety standards.
Using High-Dose Testing to 
Predict Low-Dose Effects
The core assumption of regulatory toxicol-
ogy is that experiments using high doses will 
reveal potential effects of low doses. This is 
derived from 16th-century dogma but is still 
typically applied today by federal regulators 
(White et al. 2009), although it conflicts 
directly with well-established principles in 
endocrinology regarding hormone action. 
The acceptance of this assumption has pro-
found implications for the assessment of risk 
to human health posed by EDCs.
The approach of using very high-dose test-
ing to predict consequences of much lower 
doses that are typically within the range of 
widespread human exposure emerges from a 
16th-century observation by Paracelsus that 
toxicologists paraphrase as “the dose makes 
the poison” (Gallo 1996). Paracelsus’ logic 
holds if and only if a chemical’s effects follow 
a monotonic dose–response curve, in which 
more of the chemical leads to a greater effect. 
Monotonicity and non  monotonicity refer to 
changes in the slope of the curve describing 
dose and response. Monotonic curves may 
be linear or non  linear, but the slope never 
reverses from positive to negative or vice versa. 
The slope of a non  monotonic curve changes 
sign, from positive to negative or vice versa. 
Biologically relevant non  monotonic curves 
include “U-shaped” or “inverted-U–shaped” 
dose–response relationships. When toxicolo-
gists began to focus on potential health effects 
of EDCs, endocrinolo  gists raised questions 
about the appropriateness of assuming mono-
tonicity as a basis for chemical risk assess-
ments, because non  monotonicity is a general 
charac  teristic of endogenous hormones, hor-
monally active drugs, and environmental 
chemicals with hormonal activity.
Indeed, Paracelsus’ assumption is directly 
contradicted by decades of research in endo-
crinology and clinical medicine showing that 
hormonally active compounds have dose–
response curves in which low doses can cause 
effects opposite to those at high doses. This 
issue is so central to hormone action that it 
is a critical component of determining the 
dose required for hormonally active drugs. 
Two well-known examples are Lupron [used 
to treat reproductive disorders in women and 
men (Garner 1994)] and tamoxifen [used to 
treat breast cancer (Mortimer et al. 2001)], 
in which low doses stimulate whereas high 
doses inhibit disease. Specifically, for both of 
these drugs, a phenomenon known as low-
dose “flare” occurs, during which there is 
stimulation of the response that the drug 
inhibits when the blood level of the drug 
reaches the high clinically effective dose range 
(e.g., for Lupron, testosterone secretion in 
men with prostate cancer; and for tamoxifen, 
prolifera  tion of mammary tissue in women 
with breast cancer).
Nonmonotonic Dose–Response 
Curves
Nonmonotonic dose–response curves result 
from multiple mechanisms. Hormones and 
hormone-mimicking chemicals act through 
receptors in target cells. Very low doses can 
stimulate the production of more recep-
tors (receptor up-regulation), resulting in an 
increase in responses, whereas higher doses 
(within the typical toxicologic range of chem-
ical testing) can inhibit receptors (receptor 
down-regulation), resulting in a decrease in 
responses (Welshons et al. 2003). The con-
sequence for gene activity, which is regulated 
by hormone-mimicking chemicals binding 
to receptors that amplify very small expo-
sures into very large responses, is that very 
Address correspondence to J.P. Myers, Environmental 
Health Sciences, 421 Park St., Charlottesville, VA 
22902 USA. Telephone: (434) 220-0348. Fax: (434) 
220-0347. E-mail: jpmyers@ehsic.org
We thank L. Birnbaum, P. Ehrlich, D. Epel, 
P. Hunt, D. Kennedy, P. Lee, and S. Vogel for com-
ments on the manuscript.
J.P.M. is CEO/chief scientist for Environmental 
Health Sciences (EHS), a not-for-profit organization 
that receives support from several private founda-
tions (listed at http://www.environmentalhealthnews.
org/about.html) to support EHS’s mission to 
advance public understanding of environmental 
health sciences. In addition to serving on the fac-
ulty of the University of Missouri, F.v.S. is CEO of 
XenoAnalytical LLC, a small private laboratory that 
performs assays of xenobiotic compounds. R.T.Z. 
declares he has no competing   financial interests. 
Received 10 April 2009; accepted 29 July 2009.
A Clash of Old and New Scientific Concepts in Toxicity, with Important 
Implications for Public Health
John Peterson Myers,1 R. Thomas Zoeller,2 and Frederick S. vom Saal3
1Environmental Health Sciences, Charlottesville, Virginia, USA; 2Biology Department, University of Massachusetts, Amherst, 
Massachusetts, USA; 3Division of Biological Sciences, University of Missouri, Columbia, Missouri, USA
Ba c k g r o u n d: A core assumption of current toxicologic procedures used to establish health 
  standards for chemical exposures is that testing the safety of chemicals at high doses can be used 
to predict the effects of low-dose exposures, such as those common in the general population. 
This assumption is based on the precept that “the dose makes the poison”: higher doses will cause 
greater effects.
oBjectives: We challenge the validity of assuming that high-dose testing can be used to predict 
low-dose effects for contaminants that behave like hormones. We review data from endocrinology 
and toxicology that falsify this assumption and summarize current mechanistic understanding of 
how low doses can lead to effects unpredictable from high-dose experiments.
discussion: Falsification of this assumption raises profound issues for regulatory toxicology. Many 
exposure standards are based on this assumption. Rejecting the assumption will require that these 
standards be reevaluated and that procedures employed to set health standards be changed. The 
consequences of these changes may be significant for public health because of the range of health 
conditions now plausibly linked to exposure to endocrine-disrupting contaminants.
co n c l u s i o n s: We recommend that procedures to establish acceptable exposure levels for 
  endocrine-disrupting compounds incorporate the inability for high-dose tests to predict low-dose 
results. Setting acceptable levels of exposure must include testing for health consequences at preva-
lent levels of human exposure, not extrapolations from the effects observed in high-dose experi-
ments. Scientists trained in endocrinology must be engaged systematically in standard setting for 
endocrine-disrupting compounds.
key w o r d s : biphasic, bisphenol A, dose–response curve, inverted U, low dose, nonmonotonic, 
regulatory toxicology. Environ Health Perspect 117:1652–1655 (2009).  doi:10.1289/ehp.0900887 
available via http://dx.doi.org/ [Online 30 July 2009]A clash of old and new concepts in toxicology
Environmental Health Perspectives  •  v o l u m e  117 | n u m b e r 11 | November 2009  1653
low doses of these chemicals (in the case of 
a positively regulated gene) can up-regu  late 
gene expression, whereas at higher doses the 
same chemicals down-regulate gene expres-
sion (Coser et al. 2003; Medlock et al. 1991; 
Vandenberg et al. 2007).
If only one response is being measured, 
a non  monotonic dose–response curve is a 
common finding for EDCs. An additional 
complication, however, is that when multiple 
outcomes are examined, qualitatively different 
outcomes are commonly observed at low and 
high doses of EDCs. One basis for this is that 
the suite of genes whose expression is regu-
lated by low doses of endogenous hormones 
and chemicals that mimic these hormones 
can be completely different from the genes 
affected by high doses (Coser et al. 2003). As 
the dose increases, hormones and hormone-
mimicking chemicals can bind to receptors 
for other hormones, referred to as recep-
tor cross-talk. For example, at high doses, 
endogenous and man-made environmental 
estrogens begin to inter  act with androgen 
and thyroid hormone receptors, producing 
entirely different effects from those seen at 
low doses, when only significant binding to 
estrogen receptors occurs (Welshons et al. 
2003). Furthermore, myriad hormonal feed-
back mechanisms among the brain, pituitary 
gland, and hormone-producing organs (e.g., 
thyroid gland, adrenal glands, ovaries, testes) 
contribute to the presence of non  monotonic 
dose–response curves and qualitatively differ-
ent responses at low and high doses of EDCs. 
The consequence is that high doses and low 
doses differ not just in quantitative effects but 
also in qualitative impact, especially when 
responses of whole organisms are considered.
Another consideration is that the effects 
of EDCs classified as “xeno  estrogens” are 
not identical. As research has progressed into 
identifying the molecular mechanisms medi-
ating responses, a consensus has emerged that 
this class of EDCs should be categorized as 
selective estrogen receptor modulators, to 
highlight the fact that each can result in a 
unique array of responses. However, conduct-
ing studies that involve comparing activities 
of different xeno  estrogens (or other chemi-
cals that act via simi  lar mechanisms) requires 
understanding the importance of the doses 
being used (Shioda et al. 2006). 
EDCs may also act by mechanisms that 
do not require direct mediation by classi-
cal hormone receptors. Nonspecific (non– 
receptor-mediated) toxicity can occur at high 
but not low doses. EDCs also exert actions 
upon synthesis or function of enzymes that 
may be responsible for the synthesis or 
degrada  tion of hormones and on coregulatory 
proteins that interact with receptors and, in 
the case of neuro  logic actions, affect neuro-
transmitters and their receptors (Gore 2007). 
For example, low doses of atrazine activate 
aromatase gene activity in zebrafish embryos; 
this activity can alter sex determination via a 
rapid signaling system (Suzawa and Ingraham 
2008). This concept is important because each 
of these mechanisms may have a unique dose–
response relationship for a particular EDC, 
adding to the complexity of the overall shape 
of the dose–response curve for each response.
Of great importance, above the dose at 
which a hormonally active chemical saturates 
(occupies virtually all) receptors, any change 
in response that occurs cannot be caused by a 
receptor-mediated mechanism, which requires 
a change in receptor occupancy. Receptors 
for steroid hormones are ligand-activated 
transcription factors that require a change in 
ligand binding to affect the rate of gene tran-
scription. Thus, high-dose experiments cannot 
be used to predict low-dose results mediated 
by EDCs binding to hormone receptors and 
altering receptor-mediated responses at low 
doses. The current paradigm in regulatory 
toxicology of only testing a few very high 
doses of chemicals within a relatively nar-
row dose range (with the highest dose being 
the maximum tolerated dose) thus does not 
serve to predict the hazards posed by low-level 
exposure to numerous EDCs found in most 
people in biomonitoring studies conducted 
in the United States and elsewhere (Calafat 
et al. 2008).
Nonmonotonic dose–response curves 
have been reported for adverse effects with a 
number of EDCs (Myers and Hessler 2007), 
including the polycarbonate plastic monomer 
BPA (Figure 1) used in some baby bottles, 
water bottles, and food can linings (Wetherill 
et al. 2002); di(2-ethyl  hexyl) phthalate 
(DEHP), used in medical devices and other 
products made with polyvinyl chloride plas-
tic (Takano et al. 2006); and the pesticides 
dieldrin, endosulfan, and hexa  chloro  benzene 
(Narita et al. 2007). For example, exposure to 
DEHP at a concentration 1,000-fold less than 
the current safety standard, which is based 
on high-dose liver toxicity, exacerbated aller-
gic reactions (Takano et al. 2006). Similarly, 
exposure to extremely low (picomolar, parts 
per trillion) levels of several persistent organic 
pollutants increased allergic responses (Narita 
et al. 2007). None of these effects was pre-
dicted by studies that examined only high 
doses of these chemicals.
In an experiment explicitly designed to test 
the adequacy of high-dose testing of DEHP 
in rats, Andrade et al. (2006) found that a 
high dose increased estrogen-synthesizing   
(aromatase) enzyme activity in the brains of 
neonatal male rats; a dose 100-fold lower 
appeared to be the “no effect dose,” which 
is used to estimate the dose deemed safe for 
human exposure (the aromatase enzyme is 
involved in determining sex differences in 
brain function). Only because the scientists 
broke with tradition and also tested lower 
doses did they find significant down-regulation 
of aromatase at a dose 37 times lower than the 
putative no effect dose, an effect opposite to 
and unpredicted from results of testing only 
very high doses.
Other experiments have documented 
nonmonotonicity in rat pituitary and cere-
bellar cortex cells exposed to pico  molar 
through micro  molar levels of BPA (Wozniak 
et al. 2005; Zsarnovszky et al. 2005). Acting 
Figure 1. BPA induces cell proliferation in androgen-independent LNCaP prostate cancer cells. LNCaP cells 
were propagated for 72 hr in 5% charcoal-/dextran-treated fetal bovine serum supplemented with 0.1% 
ethanol vehicle and increasing BPA concentrations (0.1–100 nM). Cells were then labeled with bromode-
oxyuridine (BrdU), and BrdU incorporation was detected via indirect immuno  fluorescence. Data shown are 
mean ± SD of three independent experiments in which at least 250 cells/experiment were analyzed. The 
shaded region indicates typical concentrations found in humans (Vandenbergh et al. 2007). The response 
to 100 nM BPA did not differ from control. A standard toxicity test, working down the dose–response curve 
from high doses, would have shown no difference between controls and exposed animals at a dose at that 
level or above and would have used it to identify the “apparent no observed adverse effect level (NOAEL),” 
indicated by the arrow. Testing at lower doses would not have been conducted, and the stimulatory effect 
of BPA at 1 nM and 10 nM would never have been observed. Figure modified from Wetherill et al. (2002). 
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through a relatively recently discovered non-
classical estrogen response system, very low 
picomolar concentrations of BPA increased 
calcium influx and activation of enzyme cas-
cades that dramatically amplify a very low-
dose signal into a large cellular response. 
The dose–response curve followed a non-
monotonic inverted-U shape, with the stron-
gest response at picomolar to low nano  molar 
levels. The bioactive concentrations of BPA 
in these experiments were below the range 
found ubiqui  tously in human blood and urine. 
Other end points that follow a non  monotonic 
pattern for BPA are human prostate cancer cell 
proliferation (Figure 1) (Wetherill et al. 2002), 
promotion of human seminoma cell prolifera-
tion (Bouskine et al. 2009), and production 
of the insulin-response–regulating hormone 
adiponectin by human adipocytes (Hugo 
et al. 2008). These specific responses to BPA 
occurred within the range of human expo-
sure to BPA based on biomonitoring stud-
ies (Calafat et al. 2008; Richter et al. 2007; 
Schonfelder et al. 2002) but were not observed 
at much higher doses.
Research over the past 20 years has iden-
tified multiple EDCs that mimic or dis-
rupt hormone function at low doses in ways 
that are not predicted by high-dose studies. 
Biomonitoring studies have established that 
many of these contaminants are widespread 
in people. Yet classical regulatory toxicology 
ignores nonmonotonicity despite the fact that, 
similar to hormones, EDCs would be expected 
to display non  monotonic dose–response pat-
terns for many responses. This disconnect with 
current science pervades virtually all regula-
tory agencies responsible for chemical safety 
around the world, and it means that many 
regulatory decisions are highly likely to have 
under  estimated risks.
Health Implications
If the health implications of these decisions 
were inconsequential, the clash between regu-
latory toxicology and endocrinology would 
appropriately remain buried in academia. But 
the range of health conditions now plausi-
bly linked to EDCs—including, but not lim-
ited to, prostate cancer (Chamie et al. 2008), 
breast cancer (Soto et al. 2008), attention 
defi  cit hyperactivity disorder (Ishido et al 
2004), infertility and male and female repro-
ductive dis  orders (Hauser and Sokol 2008; 
Swan 2008), miscarriage, and most recently, 
hyper  allergic diseases, asthma (Bornehag et al. 
2004), obesity (Hugo et al. 2008), and heart 
disease and type 2 diabetes (Lang et al. 2008; 
vom Saal and Myers 2008)—makes it impera-
tive that the clash between endocrinology and 
regu  latory toxicology be resolved in ways that 
reflect modern scientific understanding.
These chronic diseases are major contribu-
tors to the steadily increasing human disease 
burden and to the escalating cost of health 
care throughout the world. Extensive, careful, 
and replicable animal research suggests that 
numerous common man-made chemicals to 
which people are exposed every day, but that 
have not been adequately studied for health 
effects in humans, may be significant contribu-
tors to these adverse health trends. Because the 
endocrine system is highly conserved between 
animals used as models in biomedical research 
and humans, the default assumption should be 
that nonmonotonic dose–responses of EDCs 
observed in laboratory animals and in vitro, 
including with human cells and tissues, are 
applicable to human health (Hugo et al. 2008; 
Wetherill et al. 2007). Modernizing relevant 
health standards by incorporating endocrino-
logic principles could help reduce a significant 
portion of the human disease burden, but this 
will require regulatory decision makers to fun-
damentally change the paradigm commonly 
used to assess the risk to human health posed 
by chemicals.
Specific Recommendations 
and Conclusion
We recommend the following: 
• Animal testing protocols used to establish 
regulatory safety standards must include 
experiments that examine effects of chemi-
cals over a wide dose range that at their low 
end overlap with typical human exposures, 
particularly those experienced by vulnerable 
populations based on biomonitoring data, 
or modeling if actual data do not exist. 
• Current scientific knowledge obtained 
through studies on the endocrine system 
and its disruption by exogenous chemicals 
should be applied systematically when regu-
latory standards on EDCs are to be estab-
lished. For the best interest of public safety, 
cooperation of chemical manufacturers in 
reevaluating safety of their products under 
the new criteria is critical. Their acceptance 
of the endocrinology-derived concept that 
high-dose experiments are insufficient to 
establish safety standards for EDCs is essen-
tial. Continued denial of the reality that 
nonmonotonic dose–response curves are 
predicted to occur for EDCs is no longer 
tenable (Bird 2005; vom Saal 2005).
The soaring health care crisis unfolding in 
countries around the world demands that the 
regulatory apparatus of governments move 
into the 21st century. Blind obedience to 
16th-century dogma will not solve the prob-
lem. Unless and until regulatory agencies 
incorporate modern endocrinologic principles 
into their risk assessment paradigms, they 
will continue to provide false assurances of 
“safety” and fail to recognize the actual health 
risks posed by chronic low-level exposure to 
an increasing number of chemicals found in 
commonly used products.
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